Long-term study confirms atogepant safety, efficacy, and functional improvement for migraine prevention, supporting sustained use of this oral CGRP antagonist.
Key findingLong-term study confirms atogepant safety, efficacy, and functional improvement for migraine prevent
What the researchers found
Long-term study confirms atogepant safety, efficacy, and functional improvement for migraine prevention, supporting sustained use of this oral CGRP antagonist.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.
Cephalalgia : an international journal of headache, 45(8), 3331024251365206
Citation
Ashina, Sait; Ashina, Messoud; Holle-Lee, Dagny; Tassorelli, Cristina; Cho, Soo-Jin; He, Molly Yizeng; De Abreu Ferreira, Rosa; Gandhi, Pranav; Smith, Jonathan H; Pfleeger, Kimberly; Trugman, Joel M. (2025). Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.. Cephalalgia : an international journal of headache, 45(8), 3331024251365206. https://doi.org/10.1177/03331024251365206